Sutro Biopharma Inc (NASDAQ:STRO)’s Stock Is Sell After More Market Selling

The stock of Sutro Biopharma Inc (NASDAQ:STRO) registered an increase of 84.83% in short interest. STRO’s total short interest was 209,600 shares in August as published by FINRA. Its up 84.83% from 113,400 shares, reported previously. With 39,200 shares average volume, it will take short sellers 5 days to cover their STRO’s short positions. The short interest to Sutro Biopharma Inc’s float is 2.38%.

The stock decreased 0.10% or $0.01 during the last trading session, reaching $9.66. About 104 shares traded. Sutro Biopharma, Inc. (NASDAQ:STRO) has 0.00% since August 13, 2018 and is . It has by 0.00% the S&P500.

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. The company has market cap of $221.46 million. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. It currently has negative earnings. The company's product candidates include STRO-001, an antibody-drug conjugate directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers.

More notable recent Sutro Biopharma, Inc. (NASDAQ:STRO) news were published by: which released: “Sutro Appoints Industry Veteran Shalini Sharp to Board of Directors – PR Newswire” on November 08, 2018, also with their article: “Celgene backs away from collaboration programs with Sutro – Seeking Alpha” published on May 07, 2019, published: “Sutro Biopharma Announces Encouraging Interim Phase 1 Safety Data on a Potential First-in-Class Antibody-Drug Conjugate STRO-001 for the Treatment of B-cell Malignancies at the European Hematology Association Congress – PRNewswire” on June 15, 2019. More interesting news about Sutro Biopharma, Inc. (NASDAQ:STRO) were released by: and their article: “IPO News This Week: 6 Firms to Test the Market – 24/7 Wall St.” published on September 30, 2018 as well as‘s news article titled: “The Funded: Bay Area’s 12th life sciences IPO of the year is a mixed bag – Silicon Valley Business Journal” with publication date: September 28, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.